Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Quince Therapeutics, Inc. - Common Stock
(NQ:
QNCX
)
0.6417
-0.0283 (-4.22%)
Streaming Delayed Price
Updated: 10:21 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
932
Open
0.6800
Bid (Size)
0.6422 (3)
Ask (Size)
0.7000 (37)
Prev. Close
0.6700
Today's Range
0.6400 - 0.6800
52wk Range
0.5116 - 1.430
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
August 19, 2024
Via
Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
August 16, 2024
Via
Benzinga
Performance
YTD
-38.30%
-38.30%
1 Month
-13.52%
-13.52%
3 Month
-23.61%
-23.61%
6 Month
-50.26%
-50.26%
1 Year
-50.26%
-50.26%
More News
Read More
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
August 15, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024
August 13, 2024
Via
InvestorPlace
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
June 25, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
June 03, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
May 13, 2024
Via
InvestorPlace
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
May 06, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
April 02, 2024
Via
InvestorPlace
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
April 01, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Launches Scientific Advisory Board
February 22, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
February 15, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Participate at Investor Events in January 2024
January 04, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
December 08, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
December 04, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
October 23, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket
September 29, 2023
Via
Benzinga
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
September 28, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
September 06, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
August 14, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
August 10, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 24, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.